Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Iron study: Every-Other-Day dosing may boost absorption

NCT ID NCT06238895

Disease control Sponsor: Luzerner Kantonsspital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether taking oral iron every second day at double the standard dose helps people with iron deficiency absorb more iron and raise their hemoglobin faster than taking it daily. 29 adults with low iron but not severe anemia participated for 12 weeks. Researchers compared changes in hemoglobin and iron levels between the two dosing schedules.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

29 people

The number who actually took part.

Started

Mar 2024

Finished

Nov 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Informed Consent signed by the subject * ≥18 years of age * Iron deficiency: Ferritin \<30 µg/l * hemoglobin ≥ 80 g/l * CRP \< 5 mg/l Exclusion Criteria: * Refusal of study participation, * Regular administration of Erythropoietin * Oral or intravenous iron supplementation \<12 weeks prior to investigation * Contraindications to intervention medication (Tardyferon), e.g. known hypersensitivity or allergy to iron sulfate / ferrous sulfate * Blood transfusion or donation \<12 weeks prior to investigation * Active chemotherapy * Inability to follow the procedures of the investigation, e.g. due to language problems, psychological disorders, dementia, etc. of the subject. Note Due to slow recruitment, the following inclusion criterion was removed on 09/25/2024 (MM/DD/YYYY): Anemia (as defined by the WHO): Hemoglobin \<130 g/L for men, Hemoglobin \<120 g/l for women, Hemoglobin \<110 g/l for pregnant women

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Iron deficiencies are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Iron Deficiencies iron deficiency anemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Iron deficiencies Iron deficiency anemia Iron deficiency anemia treatment

Contacts and locations

Locations

  • Luzerner Kantonsspital

    Lucerne, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.